Back Back
Cell No. : Cell Name
RCB3577 : Yamato-SS  update : 2022/05/30
CommentHuman cell line derived from synovial sarcoma.
Comment from the depositor
Terms and conditionsIn publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Stem Cells 2010;28:1119-1131) designated by the DEPOSITOR is required.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Naka, Norifumi
Originator Naka, Norifumi
Year of deposit 2011
Animal human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 30 years
Tissue subcutaneous tissue of thigh
Disease name Synovial sarcoma (Stage 4)
Metastastatic ability Yes
Metastatsd tissue Lung
Classification cancer
Year of origin 2006
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_6C44
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM (high glucose, without Sodium pyruvate) + 20% FBS
Antibiotics Free
Passage method 0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
Culture information Passage ratio 1 : 6 split
SC frequency Subculture : 1-2 times/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Animal PCR OK
STR(human) OK
deposit info
lot info
Reference information Reference 9
User's Publication 4

To topTop
15489  Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T.  Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma  Cancers (Basel)  2021  13(8):1823  PubMed ID: 33920416
15896  Yasuda N, Takenaka S, Nakai S, Nakai T, Yamada S, Imura Y, Outani H, Hamada K, Yoshikawa H, Naka N.  TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma  FEBS Open Bio  2020  10(5):767-779  PubMed ID: 32128992
16158  Nakai S, Yamada S, Outani H, Nakai T, Yasuda N, Mae H, Imura Y, Wakamatsu T, Tamiya H, Tanaka T, Hamada K, Tani A, Myoui A, Araki N, Ueda T, Yoshikawa H, Takenaka S, Naka N.  Establishment of a novel human CIC-DUX 4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs  Sci Rep  2019  9(1):15812  PubMed ID: 31676869
15823  Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.  Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma  BMC Cancer  2017  17(1):334  PubMed ID: 28511645
15501  Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N.  Trabectedin is a promising antitumour agent for synovial sarcoma  J Chemother  2016  28(5):417-24  PubMed ID: 27077926
15546  Imura Y, Nakai T, Yamada S, Outani H, Takenaka S, Hamada K, Araki N, Itoh K, Yoshikawa H, Naka N.  Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma  Cancer Sci  2016  107(12):1867-1876  PubMed ID: 27779808
16270  Toru Wakamatsu, Norifumi Naka, Satoru Sasagawa, Takaaki Tanaka, Satoshi Takenaka, Nobuhito Araki, Takafumi Ueda, Yasuko Nishizawa, Hideki Yoshikawa, Kazuyuki Itoh  Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma  Cancer Sci  2014  105(9):1124-34  PubMed ID: 24975049
15415  Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, Sasagawa S, Araki N, Ueda T, Itoh K, Myoui A, Yoshikawa H.  Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001  Cancer Lett  2014  347(1):114-22  PubMed ID: 24491407
3639  Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K.  Synovial sarcoma is a stem cell malignancy.  Stem Cells.  2010  28(7):1119-31  PubMed ID: 20518020

To topTop
User's Publication
20826  Murayama Y, Kasahara Y, Kubo N, Shin C, Imamura M, Oike N, Ariizumi T, Saitoh A, Baba M, Miyazaki T, Suzuki Y, Ling Y, Okuda S, Mihara K, Ogose A, Kawashima H, Imai C.  NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma.  Transl Oncol  2022  25:101521  PubMed ID: 35998437
20170  Yamada H, Takahashi M, Watanuki M, Watanabe M, Hiraide S, Saijo K, Komine K, Ishioka C.  lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.  Oncol Lett  2021  21(6):455  PubMed ID: 33907565
20338  Murayama Y, Kawashima H, Kubo N, Shin C, Kasahara Y, Imamura M, Oike N, Ariizumi T, Saitoh A, Mihara K, Umezu H, Ogose A, Imai C.  Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma.  Transl Oncol  2021  14(12):101227  PubMed ID: 34555727
13326  Zhou F, Elzi DJ, Jayabal P, Ma X, Chiu YC, Chen Y, Blackman B, Weintraub ST, Houghton PJ, Shiio Y.  GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth.  Cell Rep  2020    PubMed ID: 33147457

Back Back Return Top Page